Engelman, Jeffrey A.

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 4,496

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 3,499

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics

PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and Cancer

Cited by 3,330

Systematic identification of genomic markers of drug sensitivity in cancer cells

Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 2,456

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Engelman, J. A. (2009) · Nature Reviews Cancer

PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and Cancer

Cited by 2,445

Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway

Viswanathan, V. S., Ryan, M. J., Dhruv, H. D., Gill, S., Eichhoff, O. M., Seashore-Ludlow, B., Kaffenberger, S. D., Eaton, J. K., Shimada, K., Aguirre, A. J., et al. (2017) · Nature

Ferroptosis and cancer prognosisCancer, Lipids, and Metabolism

Cited by 2,011

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 1,580

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 1,555

Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer

Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 1,495

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine

PI3K/AKT/mTOR signaling in cancerProtein Kinase Regulation and GTPase Signaling

Cited by 1,330

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC

Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 1,059

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 1,048

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 1,022

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 985

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., et al. (2008) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 820

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Jackman, D., Pao, W., Riely, G. J., Engelman, J. A., Kris, M. G., Jänne, P. A., Lynch, T., Johnson, B. E., & Miller, V. A. (2010) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 793

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 730

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

Crystal, A. S., Shaw, A. T., Sequist, L. V., Friboulet, L., Niederst, M. J., Lockerman, E. L., Frias, R. L., Gainor, J. F., Amzallag, A., Greninger, P., et al. (2014) · Science

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 708

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine

HER2/EGFR in Cancer ResearchColorectal Cancer Treatments and Studies

Cited by 663

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Niederst, M. J., Sequist, L. V., Poirier, J. T., Mermel, C. H., Lockerman, E. L., Garcia, A. R., Katayama, R., Costa, C., Ross, K. N., Moran, T., et al. (2015) · Nature Communications

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 647

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors

Miao, D., Margolis, C. A., Vokes, N. I., Liu, D., Taylor-Weiner, A., Wankowicz, S. M., Adeegbe, D., Keliher, D., Schilling, B., Tracy, A., et al. (2018) · Nature Genetics

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 620

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 619

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

Niederst, M. J., Hu, H., Mulvey, H. E., Lockerman, E. L., Garcia, A. R., Piotrowska, Z., Sequist, L. V., & Engelman, J. A. (2015) · Clinical Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 583

Targeting the PI3K signaling pathway in cancer

Wong, K.-K., Engelman, J. A., & Cantley, L. C. (2010) · Current Opinion in Genetics & Development

PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and Cancer

Cited by 543